Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.
Malignant Neoplasm of Stomach|Effects of Chemotherapy
DRUG: Capecitabine/Cisplatin + Sorafenib|DRUG: Capecitabine/Cisplatin
Progression-free survival, 2 years
Overall survival, 3 years|Best tumor response, 2 years|Duration of response, 2 years|Disease control rate, 2 years|Safety profiles, Toxicity profiles will be assessed with the patient 30 +/- 3 days after the last intake of study medication is required., up to 2years|Best tumoral response of 2nd line sorafenib, Best tumoral response of sorafenib in patients who progressed on capecitabine and cisplatin (control group), 2 years|Progression-free survival of 2nd line sorafenib, Progression-free survival of sorafenib in patients who progressed on capecitabine and cisplatin (control group), 2years|Biomarker for sorafenib, Blood and tumor tissue will be collected during the study, and analyzed for biomarker at the end of trial., 2years
This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.